Zinc-alpha2-glycoprotein: a new biomarker of breast cancer?

Virginie Dubois, Laetitia Delort, F Mishellany, Thierry Jarde, Hermine Billard, C Lequeux, O Damour, F Penault-Llorca, Marie-Paule Vasson, Florence Caldefie-Chezet

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


BACKGROUND/AIM: Obesity increases the risk of breast cancer. It is established that adipocyte secretions, i.e. adipokines, may play a role in mammary carcinogenesis. We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma. PATIENTS AND METHODS: Here, we evaluated zinc-alpha2-glycoprotein (ZAG) expression in tumor (n=55) and healthy (n=6) breast tissue by immunohistochemistry and examined whether it was correlated with that of major adipokines, usual tumor biomarkers (sex steroids receptors, i.e. estrogen (ER) and progesterone; Ki-67; cErb2), or apoptosis markers (Bcl2 and Bax). RESULTS: ZAG expression was detected in ductal carcinoma and normal epithelial adjacent tissue but not in normal tissue of healthy women. In cancer tissue, its expression was correlated positively to leptin receptor and negatively to adiponectin receptor and ER. CONCLUSION: These preliminary results suggest both a relationship between ZAG expression and pathways involving adipokines or estrogen and that ZAG may be a potential breast cancer biomarker.
Original languageEnglish
Pages (from-to)2919 - 2925
Number of pages7
JournalAnticancer Research
Issue number7
Publication statusPublished - 2010
Externally publishedYes

Cite this